iZafe Group AB (publ.) - announces that since the new Dosell was approved by all partners, 450 Swedish medication robots have been produced and shipped.
Our factory, like so many others, was affected by the coronavirus, which led to a near-halt in production at the beginning of the year, this led to a disruption in the production rate. We currently work at high speed and manufacture approximately 40 medication robots a week, at our factory outside Stockholm, Sweden.
“We work hard to be able to scale up production without compromising on the quality and we have high hopes that at the end of February we have been able to scale up production at a rate of about 300 Dosell a month. This is to meet the demand of our partners, who all have started the year with convincing potential customers of Dosell. All of our partners have several quotes out and negotiations underway around Dosell as a digital tool to improve and ensure that the right medicine is given in combination with Dosell being part of the digital welfare platform. Together with our partners, we have also submitted several procurements in Sweden, Norway and Finland. In order to be able to secure and fulfill the commitment in these procurements at a profit, the production rate needs to be at levels that meet the increased volumes in demand. It is gratifying that we are approaching these levels in capacity. ” says Anders Segerström, CEO, iZafe Group.